Vardenafil is a prescription phosphodiesterase type 5 (PDE5) inhibitor used to treat erectile dysfunction (ED). Although many people search for Levitra or Staxyn, those original U.S. brand products have been discontinued. U.S. regulatory records separately identify approved generic vardenafil products, so a discontinued brand does not mean that the active ingredient has disappeared from the approved market.
Product form is central to vardenafil. Conventional film-coated tablets and orally disintegrating tablets (ODT) are separately labeled; the 10 mg ODT is not interchangeable with a 10 mg film-coated tablet because exposure differs. Both formulation and exact application must therefore be confirmed rather than assuming the same milligram figure means the same directions.
This ingredient guide explains product categories, established safety considerations and where to find deeper information. The vardenafil purchasing guide covers prescription dispensing, dosage page owns the dose-selection framework, and price guide addresses cost factors. No page can determine individual eligibility or current pharmacy stock.
Vardenafil inhibits PDE5 and can support an erectile response to sexual stimulation. It does not independently create desire, treat the underlying causes of ED or guarantee an erection. Clinical response and side effects vary with individual health, other medicines, timing and the particular product prescribed.
Persistent ED deserves assessment because cardiovascular conditions, diabetes, psychological factors and medication effects may contribute. The ED condition overview describes that medical context; this ingredient hub focuses instead on U.S. vardenafil formulations and how a clinician or pharmacist identifies them.
The original Levitra conventional-tablet brand and Staxyn orally disintegrating brand are no longer marketed in the United States. Their historical labels remain relevant to understanding formulation differences, but an archived name must not be turned into a promise that a pharmacy can dispense branded stock.
FDA-listed generic applications exist for conventional vardenafil tablets and separately for vardenafil orally disintegrating tablets. Exact approvals, marketed statuses and NDC records should be checked for the product at issue, because approval does not demonstrate a pharmacy has it on hand.
| Product identity | U.S. context | Important distinction |
|---|---|---|
| Vardenafil film-coated tablets | Approved generic applications exist | As-needed ED use; product-specific strengths |
| Vardenafil ODT 10 mg | Separately approved generic products exist | Not interchangeable with film-coated 10 mg |
| Levitra | Historic brand discontinued | Not evidence of brand inventory |
| Staxyn | Historic ODT brand discontinued | Not a present branded ordering option |
Levitra’s branded U.S. products were moved to the FDA Orange Book discontinued list; FDA determined certain withdrawn Levitra strengths were not withdrawn because of safety or effectiveness. The Staxyn branded ODT product likewise appears as discontinued. These facts concern specific historical brands, not automatic revocation of all generic vardenafil approvals.
This distinction matters to shoppers who see old packaging photographs and assume the brand is available for immediate shipment. Levitra and Staxyn provide brand-specific context, while product-specific generic approval and live pharmacy inventory remain separate checks.
Vardenafil film-coated ED tablets have approved strengths that differ by product. The ODT formulation is separately labeled at 10 mg. A pharmacist should confirm the full dosage-form name, strength and prescribed directions, not select an ODT simply because a conventional tablet has the same numerical strength.
Higher systemic exposure with 10 mg ODT is stated in its prescribing information. The vardenafil ODT guide explains these non-interchangeability issues; vardenafil strengths provides a strength inventory without advising patients to choose a dose.
Conventional vardenafil ED tablets are generally prescribed for as-needed use, with labeling describing administration before anticipated sexual activity. Sexual stimulation is needed for a response. Taking a dose does not create a permanent erection, and individual timing should not be inferred from an advertisement that promises immediate action.
Formulations can differ in their instructions, including how an ODT is handled. Review how to take vardenafil for administration and onset guidance for onset, rather than using one schedule for all products sharing the vardenafil ingredient.
Vardenafil has a distinctive QT-related warning. People with congenital long QT syndrome or those using certain class IA or class III antiarrhythmic drugs require particular attention to label restrictions. This is not a detail that can be resolved by comparing brands or tablet strength on a retailer page.
A prescriber should assess cardiac history and the complete medication list before deciding on treatment. The general category comparison in the ED medications guide is useful for discussion but does not provide an individual medical clearance.
Vardenafil must not be combined with nitrates, including products used for angina, or guanylate cyclase stimulators such as riociguat. Alpha-blockers, some antihypertensives and interacting medicines also require assessment; cardiovascular suitability for sexual activity matters independently of which PDE5 inhibitor is selected.
An erection lasting longer than four hours is an emergency. Sudden vision or hearing loss requires stopping the drug and urgent clinical advice. Patients with new chest pain should obtain emergency care and disclose recent PDE5 inhibitor exposure rather than independently taking nitrate medicines.
The Orange Book can establish product-application information and therapeutic-equivalence context, while actual dispensing depends on a pharmacy, its supplier and the precise item prescribed. A pharmacy may have access to one film-coated strength yet not another, or not stock an ODT presentation.
For verification of inventory without fabricated claims, see vardenafil availability; for a nearby dispensing workflow, see local pharmacy guidance. Both should start from a valid prescription and the exact formulation.
A clinician may assess ED in person or through appropriate telehealth where permitted. Approval for a generic ingredient does not guarantee a clinician will prescribe it or a pharmacy will dispense an exact brand or dosage form. Legitimate pharmacy services require a valid prescription and access to a pharmacist.
The path from evaluation to dispensing is explained in the buying guide; remote-seller credential checks are in the online-pharmacy guide. Claims of “no prescription Levitra” or automatic substitutions between 10 mg formulations deserve particular skepticism.
Brand versus generic status, the exact formulation, prescribed quantity and the chosen pharmacy can all affect the eventual charge. Insurance benefits, pharmacist substitution and service fees must be confirmed for the specific transaction. An FDA approval database cannot supply a reliable real-time total or a guarantee of fulfillment.
Before dispensing, ask: Is the prescription for a conventional tablet or ODT? Which labeled strength? Are QT-related cautions relevant? Which interactions must be screened? What is the licensed pharmacy’s actual supply and all-in quote? These practical questions are safer than choosing a product from an unverified online catalog.
Vardenafil is an FDA-approved prescription drug ingredient used in products for erectile dysfunction. A medical evaluation is needed before treatment.
The original U.S. Levitra and Staxyn brand products are discontinued. Separate generic vardenafil approvals exist.
No. The U.S. ODT labeling specifies that they are not interchangeable, including because the ODT produces higher systemic exposure.
No. Concomitant use with nitrates is contraindicated because of the risk of a dangerous drop in blood pressure.
Its labeling contains specific QT-related precautions, including concerns with certain heart-rhythm conditions and antiarrhythmic medicines.
No. Approval and actual pharmacy inventory are separate. The pharmacy must verify the specific dosage form and strength.
No. U.S. vardenafil ED products require a valid prescription and legitimate pharmacy dispensing.
A clinician can discuss alternatives based on medical history, interacting medicines and preferred treatment approach; none is best for everyone.